Journal article
A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid (R)) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial
Franck Morschhauser, Olivier Fitoussi, Corinne Haioun, Catherine Thieblemont, Hang Quach, Richard Delarue, Sylvie Glaisner, Jean Gabarre, Andre Bosly, John Lister, Ju Li, Bertrand Coiffier
European Journal of Cancer | ELSEVIER SCI LTD | Published : 2013
Grants
Funding Acknowledgements
Funding: Celgene Corporation.